The results of a recent literature review suggest that only a high intake of vitamin D leads to a significant reduction in the risk of fracture.
The results of a recent literature review suggest that only a high intake of vitamin D leads to a significant reduction in the risk of fracture. The report, published July 5 in the New England Journal of Medicine, supports the recommendation of the Institute of Medicine that people aged 65 years and older should receive 800 IU of vitamin D per day.
Lead author, Heike A. Bischoff-Ferrari, MD, DrPH, of the University Hospital Zurich in Switzerland, and colleagues, wrote that the incidence of hip fractures in the elderly is expected to increase by 240% by the year 2050. Universal vitamin D supplementation has been one strategy discussed for curbing this trend; however, data on the benefit of vitamin D supplementation has been unclear.
The researchers examined the findings from 11 studies, including 30,011 participants aged 65 years and older, to estimate the effects of vitamin D supplementation according to the actual intake of each participant, rather than the dose to which the participant was randomly assigned.
They found that participants in the highest intake quartile (median 800 IU daily; range 792 to 2,000 IU) had a significant reduction (30%) in the risk of hip fracture and a 14% reduction in nonvertebral fracture risk, compared with controls.
“Our data suggest that high-dose vitamin D supplementation (≥800 IU per day) may reduce the risk of hip fracture in persons 65 years of age or older, independently of type of dwelling, age, and sex,” the authors wrote. “Furthermore, our data support a 25-hydroxyvitamin D level above 60 nmol per liter for the prevention of fractures.”
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More